Renal Clearable Luminescent Gold Nanoparticles: From the Bench to the Clinic

With more and more engineered nanoparticles (NPs) being translated to the clinic, the United States Food and Drug Administration (FDA) has recently issued the latest draft guidance on nanomaterial‐containing drug products with an emphasis on understanding their in vivo transport and nano–bio interac...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie International Edition 2019-03, Vol.58 (13), p.4112-4128
Main Authors: Yu, Mengxiao, Xu, Jing, Zheng, Jie
Format: Article
Language:English
Subjects:
Accumulation
Animals
Bioaccumulation
Biocompatibility
clinical translation
Gold
Gold - chemistry
Humans
Kidney - metabolism
Kidneys
Liver
Luminescence
Luminescent Agents - chemistry
Luminescent Agents - pharmacokinetics
medical imaging
Metabolic Clearance Rate
Metal Nanoparticles - administration & dosage
Metal Nanoparticles - chemistry
Nanomaterials
Nanoparticles
Protein adsorption
Proteins
Regulatory agencies
renal clearance
Tissue Distribution
Tissues
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With more and more engineered nanoparticles (NPs) being translated to the clinic, the United States Food and Drug Administration (FDA) has recently issued the latest draft guidance on nanomaterial‐containing drug products with an emphasis on understanding their in vivo transport and nano–bio interactions. Following these guidelines, NPs can be designed to target and treat diseases more efficiently than small molecules, have minimum accumulation in normal tissues, and induce minimum toxicity. In this Minireview, we integrate this guidance with our ten‐year studies on developing renal clearable luminescent gold NPs. These gold NPs resist serum protein adsorption, escape liver uptake, target cancerous tissues, and report kidney dysfunction at early stages. At the same time, off‐target gold NPs can be eliminated by the kidneys with minimum accumulation in the body. Additionally, we identify challenges to the translation of renal clearable gold NPs from the bench to the clinic. NPs get clearance: Animal studies of renal clearable gold nanoparticles from the Zheng group in the past decade are revisited from the viewpoint of in vivo transport of nanoparticles and nano–bio interactions in tissues/organs. Additionally, these results are integrated with the latest FDA guidance on nanomedicines.
ISSN:1433-7851
1521-3773
1521-3773
DOI:10.1002/anie.201807847